Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Hormone Pathay

Chemical Structure Cat. No. Product Name CAS No.
PPT Chemical Structure
BCP41931 PPT 263717-53-9
PPT, also known as Propyl pyrazole triol, is an estrogen receptor (ERalpha) agonist. PPT also exerts anti-diabetic effects in mouse models.
Giredestrant Chemical Structure
BCP39883 Giredestrant 1953133-47-5
Giredestrant is a SERD.
MB-07344 Chemical Structure
BCP41419 MB-07344 852947-39-8
MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin in rabbits, dogs and monkeys.
Norethynodrel Chemical Structure
BCP41307 Norethynodrel 68-23-5
Noretynodrel is an impurity of Norethindrone, which is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases.
Promegestone Chemical Structure
BCP41305 Promegestone 34184-77-5
Promegestone is a progestin medication which is used in menopausal hormone therapy and in the treatment of gynecological disorders.
Trimegestone Chemical Structure
BCP41300 Trimegestone 74513-62-5
Trimegestone is a steroidal progestin used as hormonal contraceptive used in hormonal replacement therapy of postmenopausal symptoms.
Boldenone Chemical Structure
BCP41298 Boldenone 846-48-0
Boldenone is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.
trans-Clomifene Citrate Chemical Structure
BCP41267 trans-Clomifene Citrate 7599-79-3
trans-Clomiphene a non-steroidal estrogen receptor antagonist. It can be used for secondary hypogonadism in overweight men wishing to restore normal testicular function.
JNJ-63576253 Chemical Structure
BCP41266 JNJ-63576253 2110428-64-1
TRC253, also known as JNJ63576253, is a potent and orally active androgen receptor antagonist.
Clomifene Chemical Structure
BCP40562 Clomifene 911-45-5
Clomiphene is a triphenylethylene nonsteroidal ovulatory stimulant evaluated for antineoplastic activity against breast cancer. Clomiphene has both estrogenic and anti-estrogenic activities that compete with estrogen for binding at estrogen receptor sites in target tissues. This agent causes the release of the pituitary gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to ovulation.
123下一頁末頁共 366 條記錄 1 / 37 頁 
<蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>